40.95 USD
↘ 0.04 (0.10%)AT CLOSE (11:59 AM EDT)
Apellis Pharmaceuticals, Inc. Common Stock
APLSNASDAQ • USD
40.96
↗ 0.01 (0.01%)
POST MARKET (AS OF 06:38 PM EDT)
Post Market
AS OF 06:38 PM EDT
40.96
↗ 0.01 (0.01%)
Market: CLOSED
Open?$40.96
High?$40.99
Low?$40.93
Prev. Close?$40.99
Volume?2.7M
Avg. Volume?7.8M
VWAP?$40.95
Rel. Volume?0.35x
Bid / Ask
Bid?$38.90 × 100
Ask?$43.01 × 100
Spread?$4.11
Midpoint?$40.96
Valuation & Ratios
Market Cap?5.2B
Shares Out?127.8M
Float?108.2M
Float %?84.6%
P/E Ratio?229.42
P/B Ratio?14.18
EPS?$0.18
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?3.13Strong
Quick Ratio?2.69Strong
Cash Ratio?1.44Strong
Debt/Equity?1.23Moderate
ValuationRICHLY VALUED
Score44/100
P/E?229.4PRICEY▾
P/B?14.18HIGH▾
P/S?5.23FAIR▾
P/FCF?116.6PRICEY▾
EV/EBITDA?91.9HIGH▾
EV/Sales?5.22FAIR▾
Returns & Efficiency
ROE?6.2%FAIR▾
ROA?2.1%WEAK▾
Cash Flow & Enterprise
FCF?$45.0M
Enterprise Value?$5.2B
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
Themes
Address
100 FIFTH AVENUE
WALTHAM, MA 02451
Phone: 617-977-5700
WALTHAM, MA 02451
Phone: 617-977-5700